These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 234293)

  • 21. Cytotoxicity reactions during immunotherapy of melanoma with neuraminidase altered autologous tumor cells.
    Miller EE; Rosato FE; Brown AS; Moskovitz A; Johnson J
    J Surg Oncol; 1976; 8(1):31-4. PubMed ID: 1249939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 23. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive transfer and specific active immunization of patients with malignant melanoma.
    Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
    Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
    Gutterman JU; Richman SP; McBride CM; Burgess MA; Bartold SL; Kennedy A; Gehan EA; Mavligit G; Hersh EM
    Recent Results Cancer Res; 1978; 68():359-62. PubMed ID: 752870
    [No Abstract]   [Full Text] [Related]  

  • 30. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
    Currie GA; McElwain TJ
    Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors.
    Berkelhammer J; Mastrangelo MJ; Laucius JF; Bodurtha AJ; Prehn RT
    Int J Cancer; 1975 Oct; 16(4):571-8. PubMed ID: 51835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 33. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of melanoma.
    Nathanson L
    J Cutan Pathol; 1979 Jun; 6(3):213-26. PubMed ID: 383755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG
    Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
    Hedley DW; McElwain TJ; Currie GA
    Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.